You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

darolutamide

Showing 26 - 50 of 65
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Female, Triple Negative and Androgen Receptor Positive Trial in Caen (Darolutamide, Capecitabine)

Active, not recruiting
  • Breast Cancer Female
  • Triple Negative and Androgen Receptor Positive
  • Caen, France
    Centre François Baclesse
Jan 3, 2022

Advanced Prostate Carcinoma, Cancer of Prostate, PSA Trial in Melbourne (Darolutamide, Radiotherapy)

Recruiting
  • Advanced Prostate Carcinoma
  • +3 more
  • Darolutamide
  • Radiotherapy
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Center
Aug 26, 2021

Prostate Cancer Trial in United States (Bicalutamide, GnRH Agonist, Radiation Therapy)

Recruiting
  • Prostate Cancer
  • Stamford, Connecticut
  • +4 more
May 12, 2022

Physical Function During ARSI Treatment

Recruiting
  • Advanced Prostate Carcinoma
  • androgen receptor signaling inhibitors
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Nov 8, 2022

Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide

Not yet recruiting
  • Prostate Adenocarcinoma
  • +2 more
  • Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
  • Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 4, 2023

Metastatic Prostate Cancer Trial in Sydney, Melbourne (Dasatinib, Darolutamide)

Recruiting
  • Metastatic Prostate Cancer
  • Sydney, New South Wales, Australia
  • +1 more
May 3, 2022

Metastatic Prostate Cancer, Castration-resistant Prostate Cancer Trial in Montréal (Darolutamide (BAY1841788), SBRT)

Recruiting
  • Metastatic Prostate Cancer
  • Castration-resistant Prostate Cancer
  • Darolutamide (BAY1841788)
  • SBRT
  • Montréal, Quebec, Canada
    Sir Mortimer JGH
Sep 20, 2021

Non-metastatic Castration-resistant Prostate Cancer Trial in India (Darolutamide (Nubeqa, BAY1841788))

Not yet recruiting
  • Non-metastatic Castration-resistant Prostate Cancer
  • Darolutamide (Nubeqa, BAY1841788)
  • Hyderabad, Andhra Pradesh, India
  • +22 more
Jul 29, 2022

Prostate Cancer Metastatic Trial in France (Darolutamide 300 mg, Placebo, Androgen deprivation therapy)

Recruiting
  • Prostate Cancer Metastatic
  • Darolutamide 300 mg
  • +2 more
  • Avignon, France
  • +44 more
Sep 28, 2022

Cerebrovascular Circulation Trial in London (Darolutamide (BAY1841788), Enzalutamide, Placebo)

Completed
  • Cerebrovascular Circulation
  • Darolutamide (BAY1841788)
  • +2 more
  • London, United Kingdom
    Centre for Neuroimaging Sciences, King's College
Oct 28, 2020

Prostate Cancer Trial in Worldwide (Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog)

Recruiting
  • Prostate Cancer
  • Darolutamide
  • +3 more
  • Boston, Massachusetts
  • +74 more
Aug 17, 2022

Prostate Cancer Trial in Worldwide (ODM-201, ADT)

Active, not recruiting
  • Prostate Cancer
  • Brussels, Belgium
  • +11 more
Jun 9, 2022

Prostate Cancer Trial in Canada (Adavosertib, Savolitinib, Darolutamide)

Recruiting
  • Prostate Cancer
  • Edmonton, Alberta, Canada
  • +10 more
May 9, 2022

Prostatic Tumors Trial in Worldwide (Darolutamide (Nubeqa, BAY1841788), Placebo, Androgen deprivation therapy (ADT))

Active, not recruiting
  • Prostatic Neoplasms
  • Darolutamide (Nubeqa, BAY1841788)
  • +2 more
  • Macquarie University, New South Wales, Australia
  • +131 more
Jan 5, 2023

Metastatic Prostate Cancer Trial in Australia, United Kingdom (AZD5305, Enzalutamide, Abiraterone Acetate)

Recruiting
  • Metastatic Prostate Cancer
  • San Diego, California
  • +25 more
Jan 10, 2023

Prostate Carcinoma Trial in United States (Darolutamide, Goserelin Acetate, Leuprolide Acetate)

Recruiting
  • Prostate Carcinoma
  • Darolutamide
  • +5 more
  • Duarte, California
  • +107 more
Jul 26, 2022

Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, NSCLC Trial in Worldwide (CCS1477, Abiraterone

Recruiting
  • Metastatic Castration-Resistant Prostate Cancer
  • +3 more
  • Boston, Massachusetts
  • +21 more
Jan 10, 2023

Biochemically Recurrent Prostate Cancer Trial in Worldwide (Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide,

Not yet recruiting
  • Biochemically Recurrent Prostate Cancer
  • Darolutamide (BAY1841788, Nubeqa)
  • +2 more
  • Phoenix, Arizona
  • +183 more
Mar 21, 2023

Prostatic Tumors Trial in Worldwide (BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy),

Active, not recruiting
  • Metastatic Hormone-sensitive Prostate Cancer
  • BAY1841788 / darolutamide (ODM-201)
  • +3 more
  • Chandler, Arizona
  • +298 more
Sep 28, 2022

Cancer Trial in Worldwide (Darolutamide (Nubeqa, BAY1841788))

Recruiting
  • Cancer
  • Darolutamide (Nubeqa, BAY1841788)
  • Homewood, Alabama
  • +335 more
Aug 8, 2022

Breast Cancer Female Trial in Canada, Germany, United States (darolutamide)

Completed
Has Results
  • Breast Cancer Female
  • darolutamide
  • Los Angeles, California
  • +13 more
Mar 19, 2020

Prostate Cancer Trial (iMAB, cMAB)

Not yet recruiting
  • Prostate Cancer
  • (no location specified)
Jul 26, 2023

Metastatic Castration-Sensitive Prostate Cancer Trial in Worldwide (AZD5305, Placebo, Abiraterone Acetate)

Not yet recruiting
  • Metastatic Castration-Sensitive Prostate Cancer
  • Tucson, Arizona
  • +192 more
Nov 6, 2023

Castration-Resistant Prostatic Tumors Trial in Worldwide (Cetrelimab 480 mg, Apalutamide 240 mg)

Completed
  • Castration-Resistant Prostatic Neoplasms
  • Cetrelimab 480 mg
  • Apalutamide 240 mg
  • San Francisco, California
  • +33 more
Feb 24, 2022

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023